Pharmacophor requirements of the aldose reductase inhibitor site

P. F. Kador, N. E. Sharpless

Research output: Contribution to journalArticlepeer-review

98 Scopus citations


Recent experimental results suggesting that diabetic pathology can at least in part be directly controlled through inhibition of the enzyme aldose reductase (alditol: NADPH oxidoreductase, EC 1.1.21) have spurred great interest in the development of specific inhibitors of this enzyme. Specific structural and electronic similarities of apparently diverse aldose reductase inhibitors have been observed through basic studies which utilize computer molecular modeling, molecular orbital calculations, known structure-activity relationships, and protein-modifications reagents such as 2-bromo-4'-nitroacetophenone. From these similarities, a model of the aldose reductase inhibitor site has been postulated along with the pharmacophor requirements for the inhibitors - guideliness which should aid in the rational design of new inhibitors.

Original languageEnglish (US)
Pages (from-to)521-531
Number of pages11
JournalMolecular pharmacology
Issue number3
StatePublished - 1983
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology


Dive into the research topics of 'Pharmacophor requirements of the aldose reductase inhibitor site'. Together they form a unique fingerprint.

Cite this